膜杰作
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax
> 【NOTCH2】
NOTCH2信息
英文名称：Neurogenic locus notch homolog protein 2
中文名称：神经源性基因座notch同源蛋白-2
靶点别称：N2ECD，NOTCH2，N2ICD，Notch 2，hN2，Neurogenic Locus Notch Homolog Protein 2，Notch (Drosophila) Homolog 2，Notch Homolog 2 (Drosophila)，Notch Homolog 2，HJCYS，AGS2，Receptor， Notch2，Notch Receptor 2
中文名称：神经源性基因座notch同源蛋白-2
靶点别称：N2ECD，NOTCH2，N2ICD，Notch 2，hN2，Neurogenic Locus Notch Homolog Protein 2，Notch (Drosophila) Homolog 2，Notch Homolog 2 (Drosophila)，Notch Homolog 2，HJCYS，AGS2，Receptor， Notch2，Notch Receptor 2
上市药物数量：0
临床药物数量：1
最高研发阶段：临床二期
临床药物数量：1
最高研发阶段：临床二期
NOTCH2 分子别名
NOTCH2, hN2, N2ECD
NOTCH2 分子背景
Functions as a receptor for membrane-bound ligands Jagged-1 (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus . Affects the implementation of differentiation, proliferation and apoptotic programs (By similarity). Involved in bone remodeling and homeostasis. In collaboration with RELA/p65 enhances NFATc1 promoter activity and positively regulates RANKL-induced osteoclast differentiation . Positively regulates self-renewal of liver cancer cells .
NOTCH2 前沿进展
NOTCH2临床药物信息
| 英文名称 | 研发代码 | 研发阶段 | 公司 | 适应症 | 临床试验 |
|---|---|---|---|---|---|
| Tarextumab | OMP-59R5 | 临床二期 | Oncomed Pharmaceuticals | 实体瘤, 胰腺癌, 小细胞肺癌 | 详情 |
